A compounded prescription capsule combining modafinil, low-dose nicotine, low-dose naltrexone, and methylene blue to support wakefulness, focus, neuroinflammation reduction, and mitochondrial energy simultaneously. It is a physician-supervised multi-mechanism cognitive formula, not a supplement.

Adults experiencing cognitive fatigue, persistent brain fog, reduced focus, or performance decline who want comprehensive multi-pathway cognitive support. It is particularly relevant for patients who have tried single-active approaches without adequate results. Provider evaluation and a full medication review are required before prescribing.

Not for use during pregnancy; albendazole is teratogenic and embryotoxic in animal studies. Women of childbearing potential should have a negative pregnancy test before starting and use effective contraception during treatment. Not for patients with known hypersensitivity to benzimidazoles. Patients with hepatic impairment require liver function monitoring given hepatic metabolism and the risk of elevated hepatic enzymes.

Modafinil reaches peak plasma levels within 2-4 hours and effects are typically noticeable the same morning. Methylene blue and nicotine act within the same timeframe. Low-dose naltrexone's endorphin rebound effect and neuroinflammation reduction build over 2-4 weeks of consistent daily use.

Yes, it is designed for once-daily morning use as directed by your provider. Some patients benefit from cycling it 5 days on and 2 days off to maintain sensitivity to modafinil and nicotine. Your provider will determine the appropriate schedule based on your goals and response.

Modafinil and naltrexone do not carry significant physical dependence risk at prescribed doses. Nicotine at therapeutic low doses in a compounded capsule carries lower addiction risk than nicotine delivery systems designed for habitual use, but the potential for nicotine dependence exists and should be discussed with your provider.

Modafinil does not release dopamine or norepinephrine like amphetamines do. It produces wakefulness and cognitive enhancement without the cardiovascular stimulation, appetite suppression, or rebound crash of Adderall. The addition of LDN, methylene blue, and nicotine covers mechanisms that stimulants entirely miss.

Moderate caffeine intake is generally compatible. However, combining modafinil with high caffeine intake can increase anxiety, jitteriness, and heart rate. Start with reduced caffeine on your first few doses to assess your individual tolerance.

Methylene blue is excreted in urine and produces a blue-green discoloration. This is completely harmless and expected. It typically resolves within 24 hours of dosing. It is not a sign of toxicity.

Describe the item or answer the question so that site visitors who are interested get more information. You can emphasize this text with bullets, italics or bold, and add links.

Modafinil is not detected on standard SAMHSA-5 workplace drug panels, but specialized athletic or military testing may screen for it. Disclose your prescription to any testing authority before submitting a sample. Naltrexone, nicotine, and methylene blue are not tested for on standard panels.

Alcohol is not recommended. Modafinil may mask the perceived sedation of alcohol while the physiological impairment remains, increasing the risk of overconsumption. LDN interacts with alcohol through the opioid receptor system. Avoid alcohol on days you take Limitless Compound.

Modafinil: headache, nausea, dry mouth, and insomnia if taken late in the day. Nicotine: mild nausea and increased heart rate at initiation. Naltrexone (low dose): vivid dreams, mild nausea, and temporary fatigue in the first 1-2 weeks. Methylene blue: blue-green urine, nausea at high doses. Rare but serious: Stevens-Johnson syndrome with modafinil and serotonin syndrome with methylene blue if taken with serotonergic medications.

Anyone on opioid medications must not use this product. Anyone on SSRIs, SNRIs, MAO inhibitors, triptans, or tramadol must not use this product due to serotonin syndrome risk from methylene blue. Not for patients with G6PD deficiency, severe hepatic impairment, uncontrolled hypertension, a history of mania or psychosis, or known hypersensitivity to any component.

Modafinil has demonstrated off-label efficacy for ADHD in clinical studies, and the nicotinic acetylcholine receptor activation from low-dose nicotine also supports attention and working memory deficits seen in ADHD. This is not an FDA-approved ADHD treatment and should be discussed with your provider in the context of your specific diagnosis and history.

The most critical interactions are methylene blue with serotonergic medications (SSRIs, SNRIs, triptans, tramadol) causing serotonin syndrome, and naltrexone with opioid medications causing precipitated withdrawal. Modafinil reduces hormonal contraceptive efficacy via CYP3A4 induction. Full medication and supplement disclosure to your provider is mandatory before prescribing.

Modafinil is FDA approved for narcolepsy and shift work disorder. Methylene blue is FDA approved as a diagnostic agent and for methemoglobinemia. Naltrexone is FDA approved at 50 mg for addiction; the low dose used here is off-label. Nicotine is FDA approved in NRT products. The compounded combination capsule is not FDA approved as a single product but is legally dispensed under physician prescription via a licensed compounding pharmacy.

Cardiovascular disease, arrhythmia, severe hepatic impairment, G6PD deficiency, and any psychiatric history including bipolar disorder or psychosis require careful provider evaluation before prescribing. A comprehensive medication review is mandatory at every visit.